Michael S. Garshick, MD Assistant Professor Department of Medicine Grossman School of Medicine NYU

Heart Disease Biomarkers, Including Lipoprotein(a) Elevated in Psoriasis

MedicalResearch.com Interview with:

Michael S. Garshick, MD Assistant Professor Department of Medicine Grossman School of Medicine NYU

Dr. Garshick

Michael S. Garshick, MD
Assistant Professor
Department of Medicine
Grossman School of Medicine

MedicalResearch.com: What is the background for this study?

Response: Patients with psoriasis have a 50% higher risk of cardiovascular disease when compared to patients without psoriasis, the mechanisms of which are still under investigation

Dyslipidemia is also highly prevalent in psoriasis including elevation in a variety of lipoproteins causal in atherosclerosis. Lipoprotein(a) is an LDL like particle which is associated with atherosclerosis, atherothrombosis, and the development of clinical cardiovascular disease. Traditionally lipoprotein(a) is felt to be inherited rather than acquired, but some evidence suggest that lipoprotein(a) is elevated in those with underlying inflammatory conditions and associated with systemic inflammation including circulating IL-6.

We therefore aimed to determine if lipoprotein(a) is elevated in psoriasis and associated with underlying systemic inflammatory profiles and biomarkers of cardiovascular risk. 

 MedicalResearch.com: What are the main findings?

Response: In this study we show a suggestive trend of elevated lipoprotein(a) in psoriasis when compared to matched controls. We show a strong association between lipoprotein(a) , Il-6 (r=0.36, p<0.01)  and IL-17A (r=0.38, p<0.01) in psoriasis. Finally, lipoprotein(a) was negatively associated with flow-mediated brachial artery reactivity (r=-0.63, p<0.01) and this association remained after adjustment for multiple covariates and confounders (β=-0.79, p<0.01).

MedicalResearch.com: What should readers take away from your report?

Response: Lipoprotein (a) is association with systemic inflammation and biomarkers of cardiovascular risk in psoriasis and may be one reason why the relative risk of a cardiovascular event is higher in patients with psoriasis.

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: Given lipoprotein(a)’s role as a cardiovascular risk enhancer in clinical cardiovascular guidelines, future studies should evaluate the utility of checking lipoprotein (a) and its prognostic implications in psoriasis.

No disclosures


ACC 21 Abstract:

Lipoprotein(A) Is Elevated In Psoriasis And Associated With Cardiovascular Risk



The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.


Last Updated on May 17, 2021 by Marie Benz MD FAAD